The Global Hepatic Encephalopathy Market, by Drug Class (Antibiotic, Laxatives, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 2,547.8 million in 2018 and is projected to exhibit a CAGR of 6.3% during the forecast period (2018 - 2026).

Increasing number of awareness programs related to hepatic encephalopathy (HE) is expected to propel the market growth. These programs focus on creating awareness among patients and healthcare professionals regarding different treatment options for HE and possible risk factors such as liver disease, hepatic cirrhosis, and hepatitis C. There are symptoms which need to be noticed to avoid further risks. The symptoms of HE can vary from person to person and may depend on the severity of the liver disease and how well the patient is able to eliminate the liver toxins. In addition, HE adversely affects sleep hygiene. Government healthcare regulatory bodies are also engaged in the hepatic encephalopathy market, supporting the research & development and awareness activities. For instance, ALIVER is the US$ 8.5 million project, funded by the EU Horizon 2020 research programme. Work started on ALIVER on January 1, 2017 and will end on September 30, 2020. The ALIVER Consortium has developed a novel and innovative liver dialysis machine that will help the liver to naturally regenerate and to keep patients alive and healthy until a donated liver is available. The American Liver Foundation is dedicated to facilitating, advocating, and promoting education, support, and research for the prevention, treatment, and cure of liver disease. The American Liver Foundation celebrates Hepatitis Awareness Month in May and urges everyone to learn what can be done to prevent the spread of hepatitis. Many forms of hepatitis are preventable and can be treated if detected early.

Browse 28 Market Data Tables and 26 Figures spread through 147 Pages and in-depth TOC on "Hepatic Encephalopathy Market, by Drug Class (Antibiotic, Laxatives, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2026"

To know the latest trends and insights related to global hepatic encephalopathy market, click the link below:

Furthermore, key players in the market are focused on adopting product development and acquisition strategies to enhance their market share, which is expected to drive growth of the market. For instance, in February 2015, Bausch Health Companies announced acquisition of Salix Pharmaceuticals for a total enterprise value of around US$ 14.5 billion. Through this acquisition, Salix's market-leading gastrointestinal franchise is an ideal strategic fit for Valeant's diversified portfolio of specialty products. In September 2016, ASKA received marketing and manufacturing approval for RIFXIMA from the Japanese regulatory authority for the treatment of hyperammonemia in HE. Based on the evidence of clinical data, the Japanese Clinical Practice Guidelines 2015 for Hepatic Cirrhosis included RIFXIMA as an effective drug for HE  to be used in Japanese clinical practice. In April 2018, Ferring Pharmaceuticals Inc. announced that they agreed for the acquisition of Rebiotix Inc. This acquisition brings together two innovative healthcare companies which share a common commitment to exploring and understanding the human microbiome to develop new solutions for patients. In September 2014, Lupin Limited and Salix Pharmaceuticals, Inc. entered into a definitive distribution agreement. According to this agreement, Salix Pharmaceuticals, Inc. granted Lupin Limited the exclusive right to market, distribute, and sell certain Salix products related to the hepatic encephalopathy in Canada. Key Takeaways of the Hepatic Encephalopathy Market:

  • The global hepatic encephalopathy market is expected to witness a CAGR of 6.3% during the forecast period (2018 – 2026), owing to increasing number of awareness programmes related to Hepatic Encephalopathy (HE).
  • Among drug class, the antibiotics segment accounted for major market share in 2017. Major pharmacological treatments for HE are non-absorbable disaccharides such as non-absorbable antibiotics. Rifaximin is the most potential antibiotic used as a therapy for HE. A significant benefit of Rifaximin is that it is minimally absorbed when taken orally—less than 0.4% of the drug is absorbed in patients with HE.
  • Among distribution channel, hospital pharmacies segment held major market share in 2017. Hospital pharmacies act as a key channel in distribution of HE treatment medications.
  • Some of the major players operating in the global hepatic encephalopathy market include, ASKA Pharmaceutical Co., Ltd., Cosmo Pharmaceuticals N.V., Lupin Limited, Kaleido Biosciences, Kannalife Sciences, Inc., Bausch Health Companies Inc., Ferring Pharmaceuticals Inc., Mallinckrodt Pharmaceuticals, Umecrine Cognition AB, and Norgine B.V.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner